Description
Release form
Pills
Packing
30 pcs.
Pharmacological action of
Betagistin acts mainly on the histamine H1 and H3 receptors of the inner ear and central vestibular nuclei. By direct agonistic action on the H1 receptors of the vessels of the inner ear, as well as indirectly through action on the NS receptors, it improves microcirculation and capillary permeability, normalizes the pressure of the endolymph in the labyrinth and cochlea. However, betahistine increases blood flow in the basilar artery.
It has a pronounced central effect, being an inhibitor of the NK receptors of the vestibular nerve nuclei. Normalizes the conductivity in neurons of the vestibular nuclei at the level of the brain stem.
The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.
Pharmacokinetics
Absorbed rapidly, binding to plasma proteins is low. The time to reach maximum plasma concentration is 3 hours. It is almost completely excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours. Half-life is 3-4 hours.
Indications
Treatment and prevention of vestibular dizziness of various origins
Syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting
Illness or Meniere’s syndrome.
Contraindications
Hypersensitivity to any of the components of the drug
age up to 18 years (due to lack of data)
pregnancy and lactation (due to lack of data).
With caution
Peptic ulcer of the stomach or duodenum (including history), pheochromocytoma, bronchial asthma. These patients should be regularly observed during treatment.
Use during pregnancy and lactation
Due to lack of data, the drug is contraindicated during pregnancy and lactation.
Special instructions
Effect on ability to drive vehicles and work with mechanisms
Betagistin does not have a sedative effect and does not affect the ability to drive a car or engage in activities that require quick psychomotor reactions.
Composition
1 tablet contains
Active ingredient: betahistine dihydrochloride 8.0 mg 16.0 mg 24.0 mg
Excipients: microcrystalline cellulose – 54.75 / 109.5 / 164.25 mg, povidone (Collidone 25) – 9.0 / 18.0 / 27.0 mg potato starch – 20.0 / 40.0 / 60.0 mg, citric acid – 2.0 / 4.0 / 6.0 mg, colloidal silicon dioxide (Aerosil ), – 3.0 / 6.0 / 9.0 mg, talc – 2.8 / 5.6 / 8.4 mg, magnesium stearate – 0.45 / 0.9 / 1.35 mg.
Dosage and Administration
Inside, with meals.
Tablets 16 mg: 1 / 2-1 tablet 3 times a day.
Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after two weeks of treatment and can increase over several months of treatment. The treatment is long. The duration of treatment is determined individually.
Side effects
Gastrointestinal upset. the appearance of hypersensitivity reactions from the skin (rash, itching, urticaria), Quincke’s edema.
Drug Interactions
Cases of interaction or incompatibility with other drugs are unknown.
Overdose
Symptoms: nausea, vomiting, convulsions.
Treatment: gastric lavage, activated carbon intake, symptomatic therapy.
Storage Conditions
In a dry, dark place at a temperature not exceeding 25 ° C. Keep out of reach of children.
Expiration date
3 years
Deystvuyushtee substance
Betagistin
dosage form
tablets
Prescription
Prescription
Adults prescribed by a doctor
